Protective effect of ocotillol against doxorubicin-induced acute and chronic cardiac injury

Molecular Medicine Reports

Volumn 9, Issue 1, 2014, Pages 360-364

  Fu, Xiaoya ^a,b   Kong, Liang ^a,b   Tang, Mingtan ^b   Zhang, Jianqiao ^b   Zhou, Xueying ^b   Li, Gang ^b   Wang, Hongbo ^b   Fu, Fenghua ^b  

^a SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b YANTAI UNIVERSITY   (China)

Author keywords

Cardiotoxicity; Doxorubicin; Ocotillol

Indexed keywords

ACUTE DISEASE; ANIMALS; CARDIOMYOPATHIES; CHRONIC DISEASE; CREATINE KINASE, MB FORM; DISEASE MODELS, ANIMAL; DOXORUBICIN; GINSENOSIDES; GLUTATHIONE; KAPLAN-MEIER ESTIMATE; LEUKOCYTE COUNT; LEUKOCYTES; MALE; MALONDIALDEHYDE; MICE; MYOCARDIUM; PROTECTIVE AGENTS;

EID: 84893819713     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1791     Document Type: Article

References (20)

1. Minotti G, Menna P, Salvatorelli E, Cairo G and Gianni L: Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229, 2004.
2. Appel JM, Nielsen D, Zerahn B, Jensen BV and Skagen K: Anthracycline-induced chronic cardiotoxicity and heart failure. Acta Oncol 46: 576-580, 2007.
3. Singal PK and Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med 339: 900-905, 1998.
4. Carvalho C, Santos RX, Cardoso S, et al: Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 16: 3267-3285, 2009.
5. Olson RD, Mushlin PS, Brenner DE, et al: Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci USA 85: 3585-3589, 1988.
6. Li L, Pan Q, Han W, Liu Z and Hu X: Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling. Clin Cancer Res 13: 6753-6760, 2007.
7. Siveski-Iliskovic N, Kaul N and Singal PK: Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 89: 2829-2835, 1994.
8. Li L, Lu Q, Shen Y and Hu X: Schisandrin B enhances doxorubicin-induced apoptosis of cancer cells but not normal cells. Biochem Pharmacol 71: 584-595, 2006.
9. Li K, Sung RY, Huang WZ, et al: Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation 113: 2211-2220, 2006.
10. Hellmann K: Overview and historical development of dexrazoxane. Semin Oncol 25: 48-54, 1998.
11. Attele AS, Wu JA and Yuan CS: Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 58: 1685-1693, 1999.
12. Karmazyn M, Moey M and Gan XT: Therapeutic potential of ginseng in the management of cardiovascular disorders. Drugs 71: 1989-2008, 2011.
13. Wang H, Yu P, Bai J, et al: Ocotillol enhanced the antitumor activity of Doxorubicin via p53-dependent apoptosis. Evidence-Based Complementary and Alternat Med 2013: 468537, 2013.
14. Rajadurai M and Stanely Mainzen Prince P: Preventive effect of naringin on cardiac markers, electrocardiographic patterns and lysosomal hydrolases in normal and isoproterenol-induced myocardial infarction in Wistar rats. Toxicology 230: 178-188, 2007.
15. Wang H, Yu P, Gou H, et al: Cardioprotective effects of 20(S)-ginsenoside Rh2 against Doxorubicin-induced cardiotoxicity in vitro and in vivo. Evid Based Complement Alternat Med 2012: 506214, 2012.
16. Zhu D, Wu L, Li CR, et al: Ginsenoside Rg1 protects rat cardiomyocyte from hypoxia/reoxygenation oxidative injury via antioxidant and intracellular calcium homeostasis. J Cell Biochem 108: 117-124, 2009.
17. Yu C, Fu F, Yu X, Han B and Zhu M: Cardioprotective effect of ocotillol, a derivate of pseudoginsenoside F11, on myocardial injury induced by isoproterenol in rats. Arzneimittelforschung 57: 568-572, 2007.
18. Papadopoulou LC and Tsiftsoglou AS: Effects of hemin on apoptosis, suppression of cytochrome c oxidase gene expression, and bone-marrow toxicity induced by doxorubicin (adriamycin). Biochem Pharmacol 52: 713-722, 1996.
19. Palma MD, Lombardi G, Donach ME, et al: Tolerability of PLD/oxaliplatin regimen in recurrent ovarian cancer patients with previous fragility to carboplatin/paclitaxel treatment. Am J Clin Oncol 34: 305-308, 2011.
20. Wang S, Konorev EA, Kotamraju S, Joseph J, Kalivendi S and Kalyanaraman B: Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H2O2- and p53-dependent pathways. J Biol Chem 279: 25535-25543, 2004.